JPWO2020257573A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257573A5 JPWO2020257573A5 JP2021575994A JP2021575994A JPWO2020257573A5 JP WO2020257573 A5 JPWO2020257573 A5 JP WO2020257573A5 JP 2021575994 A JP2021575994 A JP 2021575994A JP 2021575994 A JP2021575994 A JP 2021575994A JP WO2020257573 A5 JPWO2020257573 A5 JP WO2020257573A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- crystalline
- salt
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000013078 crystal Substances 0.000 claims 12
- 108010011485 Aspartame Proteins 0.000 claims 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 6
- 229960003438 aspartame Drugs 0.000 claims 6
- 235000010357 aspartame Nutrition 0.000 claims 6
- 239000000605 aspartame Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 5
- 159000000007 calcium salts Chemical class 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical class NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- 150000004885 piperazines Chemical class 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864873P | 2019-06-21 | 2019-06-21 | |
| US62/864,873 | 2019-06-21 | ||
| PCT/US2020/038624 WO2020257573A1 (en) | 2019-06-21 | 2020-06-19 | Salt forms of bempedoic acid and methods for using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536979A JP2022536979A (ja) | 2022-08-22 |
| JP2022536979A5 JP2022536979A5 (https=) | 2023-06-16 |
| JPWO2020257573A5 true JPWO2020257573A5 (https=) | 2023-06-16 |
Family
ID=71528020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575993A Pending JP2022537049A (ja) | 2019-06-21 | 2020-06-19 | ベンペド酸の製造方法及びその組成物 |
| JP2021575994A Withdrawn JP2022536979A (ja) | 2019-06-21 | 2020-06-19 | 塩形態のベンペド酸及びそれを使用する方法 |
| JP2024211105A Pending JP2025032197A (ja) | 2019-06-21 | 2024-12-04 | ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575993A Pending JP2022537049A (ja) | 2019-06-21 | 2020-06-19 | ベンペド酸の製造方法及びその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024211105A Pending JP2025032197A (ja) | 2019-06-21 | 2024-12-04 | ベンペド酸を含む製薬材料、医薬製剤及び医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (10) | US12344578B2 (https=) |
| EP (3) | EP3986860A1 (https=) |
| JP (3) | JP2022537049A (https=) |
| KR (3) | KR20250143358A (https=) |
| CN (3) | CN112437766A (https=) |
| AU (3) | AU2020296094B2 (https=) |
| BR (1) | BR112021025964A2 (https=) |
| CA (3) | CA3144372A1 (https=) |
| ES (1) | ES3032779T3 (https=) |
| HU (1) | HUE072061T2 (https=) |
| IL (3) | IL288909A (https=) |
| MX (2) | MX2021015936A (https=) |
| WO (2) | WO2020257571A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112437766A (zh) | 2019-06-21 | 2021-03-02 | 艾斯柏伦治疗公司 | 制备贝派地酸及其组合物的方法 |
| CN114746389A (zh) | 2019-10-03 | 2022-07-12 | 斯索恩有限公司 | 贝派地酸的晶形 |
| US12516013B2 (en) | 2019-12-06 | 2026-01-06 | Synthon B.V. | Crystalline forms of sodium salt of Bempedoic acid |
| CN111559961A (zh) * | 2020-05-26 | 2020-08-21 | 杭州科巢生物科技有限公司 | 一种贝派地酸晶型及其制备方法 |
| WO2021255180A1 (en) * | 2020-06-19 | 2021-12-23 | Synthon B.V. | Salts of bempedoic acid |
| CN112521282A (zh) * | 2020-12-02 | 2021-03-19 | 苏州汉德创宏生化科技有限公司 | 一种贝派地酸中间体及其合成方法 |
| WO2022149161A1 (en) * | 2021-01-05 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Process for preparation of bempedoic acid and its intermediates |
| WO2022256378A1 (en) | 2021-06-02 | 2022-12-08 | Esperion Therapeutics, Inc. | Compositions containing and therapies using bempedoic acid and tolvaptan |
| CN115504914B (zh) * | 2021-06-23 | 2024-05-07 | 武汉武药科技有限公司 | 一种贝派地酸中间体的制备方法 |
| CN114436837B (zh) * | 2021-12-27 | 2024-02-20 | 甘李药业股份有限公司 | 一种贝派地酸中间体的纯化方法 |
| WO2023187833A1 (en) * | 2022-03-30 | 2023-10-05 | Enaltec Labs Private Limited | A novel salt of bempedoic acid |
| CN117551009A (zh) * | 2022-08-05 | 2024-02-13 | 武汉武药科技有限公司 | 一种贝派地酸中间体的合成方法 |
| WO2024151311A1 (en) | 2023-01-09 | 2024-07-18 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
| CN116589341A (zh) * | 2023-04-14 | 2023-08-15 | 苏州汉德创宏生化科技有限公司 | 一种抗高血酯药物中间体的制备方法 |
| TW202539678A (zh) | 2024-03-20 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| TW202602886A (zh) | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| TW202602866A (zh) | 2024-03-20 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | Ｐｃｓｋ９抑制劑及其使用方法 |
| WO2025238159A1 (en) | 2024-05-16 | 2025-11-20 | Astrazeneca Ab | Combination therapy comprising azd0780 and ezetimibe |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3152148A (en) | 1963-01-03 | 1964-10-06 | Dow Chemical Co | Preparation of comenic and pyromeconic acids |
| US3441605A (en) | 1965-02-17 | 1969-04-29 | Wallace & Tiernan Inc | Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation |
| FR1545224A (fr) | 1966-12-21 | 1968-11-08 | Geigy Ag J R | Procédé de préparation de l'acide sébacique |
| GB1196595A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a Lactone |
| GB1196598A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a Ketosebacic Acid |
| GB1196597A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of an Oxido-Cyclodecene |
| GB1196596A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Preparation of a hydroxysebacic acid |
| GB1196594A (en) | 1966-12-21 | 1970-07-01 | Geigy Uk Ltd | Improvements in and relating to the production of Sebacic Acid |
| US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| US4281200A (en) | 1979-08-30 | 1981-07-28 | The Dow Chemical Company | Catalytic process for converting oxazolidinones to their corresponding aminoalcohols |
| JPS5639033A (en) | 1979-09-04 | 1981-04-14 | Kao Corp | Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same |
| IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| IT1164254B (it) | 1983-05-30 | 1987-04-08 | Luso Farmaco Inst | 3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione |
| JPS59232811A (ja) | 1983-06-16 | 1984-12-27 | Sumitomo Chem Co Ltd | 芳香族ポリアミドイミド樹脂成形体の製造方法 |
| JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US4896344A (en) | 1984-10-15 | 1990-01-23 | Grady John K | X-ray video system |
| US4634119A (en) | 1985-07-11 | 1987-01-06 | Pesthy Paul K | Resilient exercise machine with body support platform |
| US4714762A (en) | 1986-10-31 | 1987-12-22 | Warner-Lambert Company | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5225439A (en) | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US5428062A (en) | 1987-01-28 | 1995-06-27 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
| US4758880A (en) | 1987-03-27 | 1988-07-19 | The Grass Valley Group, Inc. | Video matte generator |
| JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Ｄｎａおよびその用途 |
| US5254589A (en) | 1991-10-15 | 1993-10-19 | Warner-Lambert Company | Sulfonyl urea and carbamate ACAT inhibitors |
| IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| US5420339A (en) | 1993-11-22 | 1995-05-30 | Warner-Lambert Company | Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors |
| JP2937012B2 (ja) | 1994-04-08 | 1999-08-23 | 時久 増田 | 角筒包装袋の製造方法及び装置 |
| US5578639A (en) | 1994-07-01 | 1996-11-26 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| US5504073A (en) | 1994-07-01 | 1996-04-02 | Warner-Lambert Company | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| WO1997016184A1 (en) | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
| JP4139448B2 (ja) | 1996-08-13 | 2008-08-27 | 信越化学工業株式会社 | α−ブロモ，ω−クロロアルカンの製造方法 |
| US5807846A (en) | 1996-11-14 | 1998-09-15 | Warner-Lambert Company | Phosphonamide ACAT inhibitors |
| IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| US6093744A (en) | 1997-04-21 | 2000-07-25 | Warner-Lambert Company | N-acyl sulfamic acid esters useful as hypocholesterolemic agents |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| NZ503598A (en) | 1997-11-25 | 2002-06-28 | Warner Lambert Co | Hydroxylated gemfibrozil, atorvastatin and fluvastatin with antioxidant activity for inhibition of lipoprotein oxidation |
| MXPA01009893A (es) | 1999-04-01 | 2003-07-28 | Esperion Therapeutics Inc | Compuestos con eter, composiciones y usos de estos. |
| AU2002211666A1 (en) | 2000-10-11 | 2002-04-22 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| MXPA03003024A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de sulfoxido y bis-sulfoxido y composiciones para el control de colesterol y usos relacionados. |
| US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| WO2002030860A2 (en) | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| IL155215A0 (en) | 2000-10-11 | 2003-11-23 | Esperion Therapeutics Inc | Ether compounds and compositions for cholesterol management and related uses |
| US7053046B2 (en) | 2001-12-21 | 2006-05-30 | Mcgrath Kevin | Peptide activators of VEGF |
| HUE036646T2 (hu) | 2003-01-23 | 2018-07-30 | Esperion Therapeutics Inc | Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra |
| JP2007525408A (ja) | 2003-12-24 | 2007-09-06 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連使用のためのケトン化合物および組成物 |
| JP4553181B2 (ja) | 2004-03-25 | 2010-09-29 | 株式会社サタケ | 残留農薬分析方法 |
| US8209479B2 (en) | 2007-07-18 | 2012-06-26 | Google Inc. | Memory circuit system and method |
| US10028926B2 (en) | 2012-01-06 | 2018-07-24 | Gemphire Therapeutics Inc. | Methods of reducing risk of cardiovascular disease |
| US9662307B2 (en) * | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US20160058751A1 (en) | 2013-03-28 | 2016-03-03 | Cellworks Group, Inc. | Composition and method for treating cancer |
| WO2015018060A1 (en) * | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| RU2022102472A (ru) | 2015-03-13 | 2022-03-15 | Эсперион Терапеутикс, Инк. | Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2017023165A1 (en) | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| WO2018148417A1 (en) | 2017-02-08 | 2018-08-16 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease |
| TW201906599A (zh) | 2017-05-11 | 2019-02-16 | 美商珍費爾醫療公司 | 吉卡賓組成物及其使用方法 |
| US20180338922A1 (en) | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| CN107628975B (zh) * | 2017-09-17 | 2019-10-29 | 贵州医科大学 | 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用 |
| CN109721486A (zh) * | 2017-10-31 | 2019-05-07 | 鲁南制药集团股份有限公司 | 一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法 |
| KR20200123181A (ko) | 2018-02-16 | 2020-10-28 | 에스페리온 테라피유틱스 인코포레이티드 | 뱀페도익산의 지속 방출형 제제 |
| EP3666750A1 (en) * | 2018-12-10 | 2020-06-17 | Sandoz AG | Crystalline form of bempedoic acid |
| JP2022516530A (ja) * | 2018-12-31 | 2022-02-28 | ルピン・リミテッド | ベンペド酸の新規塩及び多形体 |
| CN112437766A (zh) | 2019-06-21 | 2021-03-02 | 艾斯柏伦治疗公司 | 制备贝派地酸及其组合物的方法 |
| US12516013B2 (en) * | 2019-12-06 | 2026-01-06 | Synthon B.V. | Crystalline forms of sodium salt of Bempedoic acid |
| WO2022149161A1 (en) | 2021-01-05 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Process for preparation of bempedoic acid and its intermediates |
-
2020
- 2020-06-19 CN CN202080003150.1A patent/CN112437766A/zh active Pending
- 2020-06-19 KR KR1020257031641A patent/KR20250143358A/ko active Pending
- 2020-06-19 EP EP20737751.6A patent/EP3986860A1/en not_active Withdrawn
- 2020-06-19 BR BR112021025964A patent/BR112021025964A2/pt not_active Application Discontinuation
- 2020-06-19 CA CA3144372A patent/CA3144372A1/en active Pending
- 2020-06-19 KR KR1020227002107A patent/KR20220024815A/ko not_active Withdrawn
- 2020-06-19 CA CA3144371A patent/CA3144371A1/en active Pending
- 2020-06-19 CN CN202211022415.XA patent/CN115429784A/zh active Pending
- 2020-06-19 JP JP2021575993A patent/JP2022537049A/ja active Pending
- 2020-06-19 MX MX2021015936A patent/MX2021015936A/es unknown
- 2020-06-19 CA CA3243601A patent/CA3243601A1/en active Pending
- 2020-06-19 AU AU2020296094A patent/AU2020296094B2/en active Active
- 2020-06-19 WO PCT/US2020/038622 patent/WO2020257571A1/en not_active Ceased
- 2020-06-19 HU HUE20737750A patent/HUE072061T2/hu unknown
- 2020-06-19 MX MX2021015935A patent/MX2021015935A/es unknown
- 2020-06-19 CN CN202080003148.4A patent/CN112437765A/zh active Pending
- 2020-06-19 WO PCT/US2020/038624 patent/WO2020257573A1/en not_active Ceased
- 2020-06-19 AU AU2020295503A patent/AU2020295503A1/en not_active Abandoned
- 2020-06-19 ES ES20737750T patent/ES3032779T3/es active Active
- 2020-06-19 KR KR1020227002108A patent/KR20220024816A/ko active Pending
- 2020-06-19 EP EP24194322.4A patent/EP4438114A3/en active Pending
- 2020-06-19 US US17/620,885 patent/US12344578B2/en active Active
- 2020-06-19 JP JP2021575994A patent/JP2022536979A/ja not_active Withdrawn
- 2020-06-19 EP EP20737750.8A patent/EP3986859B1/en active Active
-
2021
- 2021-01-15 US US17/150,325 patent/US11407705B2/en active Active
- 2021-01-15 US US17/150,321 patent/US20210139405A1/en not_active Abandoned
- 2021-12-12 IL IL288909A patent/IL288909A/en unknown
- 2021-12-14 IL IL288997A patent/IL288997A/en unknown
-
2022
- 2022-01-18 US US17/577,829 patent/US11760714B2/en active Active
- 2022-05-12 US US17/742,728 patent/US11613511B2/en active Active
- 2022-07-19 US US17/867,744 patent/US11987548B2/en active Active
-
2023
- 2023-04-10 US US18/297,846 patent/US11926584B2/en active Active
- 2023-08-16 US US18/450,591 patent/US12404227B2/en active Active
-
2024
- 2024-04-11 US US18/632,996 patent/US20240286987A1/en active Pending
- 2024-05-07 US US18/657,105 patent/US12398087B2/en active Active
- 2024-12-04 JP JP2024211105A patent/JP2025032197A/ja active Pending
-
2025
- 2025-05-06 AU AU2025203232A patent/AU2025203232A1/en active Pending
- 2025-10-19 IL IL324076A patent/IL324076A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020257573A5 (https=) | ||
| JPWO2022138988A5 (https=) | ||
| JP2025013344A5 (https=) | ||
| JP2024071370A5 (https=) | ||
| RU2080116C1 (ru) | Средство для лечения болей или воспалений | |
| JP2023036708A5 (https=) | ||
| CN1382682A (zh) | 2－(α－羟基戊基)苯甲酸盐及其制法和用途 | |
| CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
| BRPI0702875A2 (pt) | formas cristalinas de tigeciclina e seus processos de preparação | |
| JP2023109937A5 (https=) | ||
| JPWO2020010068A5 (https=) | ||
| RU2002113169A (ru) | Измельченная форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| RU2002113450A (ru) | Кристаллическая форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| JP2009143954A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| JPWO2022221227A5 (https=) | ||
| JP2013516475A5 (https=) | ||
| JPWO2020051538A5 (https=) | ||
| RU2002135315A (ru) | Производные хинолонкарбоновой кислоты | |
| JP2021530440A5 (https=) | ||
| RU2007143025A (ru) | Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты | |
| CN101516191A (zh) | Saha的胺碱盐和其多晶型物 | |
| JP7126520B2 (ja) | Ｌ－オルニチンフェニルアセテートを製造する方法 | |
| JPWO2023163203A5 (https=) | ||
| TWI905319B (zh) | Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和/或治療腎病的藥物中的用途 | |
| JPWO2019234240A5 (https=) |